The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Rhumbline Advisers slightly reduced its stake in Regeneron Pharmaceuticals (NASDAQ:REGN) by 1.6% during the third quarter. The investment firm divested 2,658 shares, bringing its total holdings to 168,001 shares valued at approximately $94.46 million. This adjustment by Rhumbline comes as several other institutional investors, including CoreCap Advisors and Parkside Financial Bank & Trust, notably increased their positions in REGN. Furthermore, Regeneron Pharmaceuticals recently reported robust quarterly earnings that surpassed analyst expectations. The biotechnology company also demonstrated financial strength by raising its quarterly dividend, signaling confidence in its future performance. Despite Rhumbline's minor reduction, the overall institutional sentiment appears mixed to positive, supported by Regeneron's strong fundamentals.
Sign in to access this content
Sign In